The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease
Viridian Therapeutics recently received FDA approval for Lumvoa, an IGF-1R antagonist, to treat both active and chronic thyroid eye disease. This marks Viridian's first commercial product and introduces a new therapy with comprehensive labeling for TED, including data on diplopia response and complete resolution. The investment focus for Viridian shifts to commercial uptake and real-world safety, with prior volatility and unprofitability serving as key risks.
VRDN - Viridian Therapeutics Inc Earnings
This article provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also presents earnings per share (EPS) forecasts, insider and institutional ownership data, profitability margins, and stock performance metrics across different timeframes.
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN)
This article analyzes hypothetical investments in Viridian Therapeutics Inc (VRDN), detailing the returns of $1,000 invested over 1, 5, and 10 years, and comparing its performance to the S&P 500. It also provides an in-depth company profile, outlining Viridian's focus on developing therapies for serious and rare diseases, particularly thyroid eye disease (TED), through its antibody discovery and protein engineering expertise. The company's lead candidates, veligrotug and elegrobart (VRDN-003), are discussed, along with its FcRn inhibitor programs and collaborations.
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Shares of Viridian Therapeutics (VRDN) rose 6.3% last week following FDA approval for veligrotug (brand name Lumvoa) for thyroid eye disease (TED), marking the company's entry into the commercial biotechnology sector. Lumvoa is the first FDA-approved TED therapy with labeling for both active and chronic disease. Viridian also has elegrobart, another TED candidate, with plans for a BLA submission in Q1 2027.
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian Therapeutics (VRDN) shares rose 6.3% last week following FDA approval of veligrotug (brand name Lumvoa) for thyroid eye disease (TED). This approval marks the company's transition to a commercial-stage biotechnology company and is significant for TED treatment as it includes data for both active and chronic forms of the disease. Viridian also has another pipeline candidate, elegrobart, which is an subcutaneous program for TED and is expected to have its Biologics License Application submitted in Q1 2027.
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more
This edition of Rx Rundown covers significant news in the medical marketing and pharmaceutical industry. Key highlights include Zymeworks acquiring Theravance Biopharma, several FDA approvals and rejections for new and existing drugs, and substantial funding rounds for various biotech companies. The article also notes BioCryst's decision to close its Discovery Center and cut its operating expense forecast.
VRDN - Viridian Therapeutics Inc Options
This page provides a detailed financial overview of Viridian Therapeutics Inc (VRDN), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short interest data, alongside stock performance over different periods.
Viridian Therapeutics (VRDN) Wins FDA Approval For Lumvoa, Is The Upside Already Priced In?
Viridian Therapeutics (VRDN) recently received FDA approval for Lumvoa, its treatment for thyroid eye disease, leading to a 6% after-hours stock increase. Despite a 40.11% year-to-date drop, the stock shows a 26.99% one-year return, prompting questions about its current valuation. Simply Wall St's analysis indicates the stock is overvalued based on a P/S ratio of 28.6x compared to industry averages, an SWS DCF model, however, suggests it is deeply undervalued with a fair value of $135.06 against its current $18.38 share price.
FDA clears Viridian's veligrotug for TED as Lumvoa
Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking it as the second FDA-approved treatment for the condition. Lumvoa is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, indicated for TED regardless of activity or duration, and plans for an immediate U.S. commercial launch are underway. The therapy distinguishes itself by being the first approved product for TED to show a statistically significant effect in both diplopia response and complete resolution of diplopia in active and chronic disease.
Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED)
Viridian Therapeutics announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), following priority review and support from the THRIVE and THRIVE-2 clinical trials. The company plans an immediate launch and has established ViridianCares, a patient support program, to ensure broad access. This approval marks Viridian's first FDA-approved medicine, offering a new treatment option for the full spectrum of TED, including rapid reduction of proptosis and improvement in diplopia.
Viridian Therapeutic stock rating reiterated at Outperform by William Blair
William Blair has reiterated its Outperform rating on Viridian Therapeutic (NASDAQ:VRDN) following the company's recent discussion of its newly FDA-approved treatment for thyroid eye disease, Lumvoa. The firm expressed increased confidence in Viridian's commercial readiness and the long-term market opportunity for Lumvoa, an optimism shared by other analysts and supported by InvestingPro data indicating the stock is currently undervalued. This approval marks Viridian's transition from a developmental biotech to a commercial entity, with significant upside potential suggested by analyst price targets.
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
Analysts are showing bullish sentiment towards several healthcare stocks, including Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595), and Sino Biopharmaceutical (SBMFF). Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeutics with a price target of $32.00, citing a Strong Buy consensus for the company. This optimism comes amid recent developments for Viridian Therapeutics, including FDA approval and trial completions.
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics has received U.S. FDA approval for Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED), marking the company's first commercial product. Lumvoa is the first approved treatment for TED with data for both active and chronic forms of the disease, demonstrating rapid and significant improvements in key symptoms. Viridian plans an immediate launch, supported by a comprehensive patient support program, and will host a conference call on June 29, 2026, to discuss the approval.
Why Viridian Therapeutics (VRDN) Is Up 7.6% After FDA Clears First All‑Stage Thyroid Eye Drug
Viridian Therapeutics' stock rose by 7.6% after its drug Lumvoa received FDA approval to treat thyroid eye disease across all stages, making it the first such therapy. This approval shifts Viridian from a development-stage company to a commercial one, with potential for further market expansion if its second TED product, elegrobart, is also approved. Despite the positive catalyst, the company faces execution risks, including launch uptake, spending discipline, and future funding needs, alongside divergent analyst valuations.
Price to earnings forward of Viridian Therapeutics, Inc. – NASDAQ:VRDN
This article provides financial information for Viridian Therapeutics, Inc. (NASDAQ:VRDN), specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed at the time of publication and offers an overview of the company's financial data on TradingView. The page serves as a data point for investors interested in VRDN's valuation metrics.
Price to earnings forward of Viridian Therapeutics, Inc. – GETTEX:1S1
The article displays the "Price to earnings forward" for Viridian Therapeutics, Inc. (1S1) traded on Gettex, indicating that the market was closed with no trades recorded for this metric. It also mentions that the data is provided by ICE Data Services and FactSet, and refers to SEC filings by Quartr.
Viridian’s Lumvoa becomes the first FDA-approved TED treatment
Viridian Therapeutics has received FDA approval for Lumvoa (veligrotug-vvze) to treat Thyroid Eye Disease (TED), making it the first approved TED treatment with data for both active and chronic forms of the condition. The approval is supported by positive results from the THRIVE and THRIVE-2 clinical trials, which demonstrated significant improvements in TED symptoms. Viridian plans an immediate launch of Lumvoa, supported by a comprehensive patient support program, and will host a conference call on June 29 to discuss the approval.
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
Viridian Therapeutics Inc (VRDN) saw its stock jump 6% after-hours following FDA approval of its drug, Lumvoa, for thyroid eye disease (TED). Lumvoa is the first treatment for TED approved for both active and chronic stages of the condition. The approval is based on strong results from two late-stage trials, and Viridian has immediately launched Lumvoa and a patient support program.
Paradigm entities report combined stake in Viridian Therapeutics (NASDAQ: VRDN)
Paradigm BioCapital Advisors and affiliated entities have reported a combined stake in Viridian Therapeutics (NASDAQ: VRDN) through a Schedule 13G SEC filing. Paradigm BioCapital Advisors and related entities beneficially own 5.1% (5,633,788 shares), while Paradigm BioCapital International Fund Ltd. beneficially owns 4.5% (4,942,532 shares) as of June 18, 2026. The filing indicates passive investment with sole voting and dispositive power for each reporting person based on 110,427,682 outstanding shares as of May 11, 2026.
Viridian Therapeutics, Inc. Actuals & Estimates (NASDAQ:VRDN)
This article provides an overview of Viridian Therapeutics, Inc. (VRDN) including its current stock price, market capitalization, and analyst forecasts. It details financial actuals and estimates for earnings and revenue, notes the company's next earnings report date, and discusses historic price performance and volatility.
Viridian Therapeutics, Inc. Actuals & Estimates (FWB:1S1)
This article provides an overview of Viridian Therapeutics, Inc. (FWB:1S1) including financial actuals and estimates, stock forecasts, historical prices, and key financial metrics. It highlights analyst price targets ranging from 17.23 EUR to 43.07 EUR and details past earnings, revenue, and net income figures. The company's next earnings report is scheduled for August 12, 2026, and it does not pay dividends.
1S1 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Viridian Therapeutics, Inc. (1S1) stock, including analyst price targets, past performance, and upcoming earnings dates. It highlights that 16 analysts forecast a price target of 29.24 EUR, with a max estimate of 43.07 EUR and a min estimate of 17.23 EUR. The company is expected to release its next earnings report on August 12, 2026, and does not pay dividends.
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Viridian Therapeutics Inc (VRDN), stating its current valuation score is 6.86, which ranks 267 out of 389 in the Biotechnology & Medical Research industry. It notes the company's current P/E ratio is -4.32, which is significantly below its recent high and above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Should Surging Big‑Ticket Ownership Amid Ongoing Losses Require Action From Viridian Therapeutics (VRDN) Investors?
Viridian Therapeutics (VRDN) has seen a significant increase in institutional ownership, including by Fidelity and BlackRock, despite ongoing losses and limited operating efficiency. While the company is reporting higher revenue and net profit, its investment narrative relies heavily on the success of its TED franchise and managing dilution. Investors should consider multiple perspectives and analyze the company's financial health before making investment decisions.
Should Surging Big‑Ticket Ownership Amid Ongoing Losses Require Action From Viridian Therapeutics (VRDN) Investors?
Viridian Therapeutics has seen a significant increase in institutional ownership from major investors, despite continuing to report losses, although revenue and net profit are improving. This rise in big-ticket investment indicates a degree of confidence, but also highlights the execution risks as the company relies on future FDA approvals for its TED franchise amidst negative earnings and a rich sales multiple. Investors need to weigh these perspectives, focusing on upcoming catalysts and the company's ability to manage dilution and commercialization.
Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying
Viridian Therapeutics (VRDN) has gained investor attention due to increased institutional ownership and strong quarterly revenue and net profit growth. Despite a high price-to-sales multiple of 25.9x, indicating overvaluation against peers, Simply Wall St's discounted cash flow (DCF) model suggests a fair value of $109.67 per share, significantly above its current trading price of $16.63. Investors are left to weigh the high P/S ratio against the DCF model's optimistic valuation, considering the company's current loss-making status.
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Viridian Therapeutics Inc (VRDN), although it states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It lists some basic financial information for VRDN, including its market capitalization and current stock price. The only specific revenue figure mentioned is $70.85 million for the United States, but without a proportion, suggesting incomplete data.
Viridian Therapeutics Inc (VRDN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Viridian Therapeutics Inc (VRDN), highlighting its current earnings forecast score, average price target from analysts, and a comparison with peers in the Biotechnology & Medical Research industry. It also includes expected revenue and EPS for upcoming quarters, based on analyst ratings. The majority of analysts recommend a "Buy" for VRDN stock.
Viridian Therapeutics (VRDN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Viridian Therapeutics provided an update at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting anticipated commercial approval for its treatment with a PDUFA date of June 30, along with positive results from subcutaneous REVEAL-1 and REVEAL-2 studies targeting a BLA submission in Q1 2027. The company's commercial strategy involves a fully hired sales force of nearly 100, focusing on core prescribers and leveraging product differentiation through rapid onset and potential broad indication in thyroid eye disease (TED). Viridian also expects to advance its TSHR and FcRn programs, revealing further development steps later in the year.
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $35
Goldman Sachs has reiterated its Buy rating on Viridian Therapeutics (VRDN.US) and increased its price target from $33 to $35. This adjustment reflects continued confidence in the company's prospects.
VRDN: Approval expected June 30, with launch-ready teams and strong clinical differentiation
Viridian Therapeutics, Inc. (VRDN) anticipates commercial approval for its product by June 30, supported by fully operational launch teams and a trained sales force targeting 2,000 core prescribers. The company highlights its differentiated clinical data and subcutaneous options, positioning its portfolio for wide adoption in both active and chronic thyroid eye disease. This information is based on a Goldman Sachs conference transcript.
Does Viridian Therapeutics (VRDN) Early Debt Repayment Reveal a New Capital Discipline Strategy?
Viridian Therapeutics recently repaid a US$55.1 million term loan ahead of schedule and raised US$125 million through an equity offering. This move swaps expensive debt for equity dilution, improving near-term financial flexibility but not changing the core investment narrative, which remains tied to upcoming milestones for its thyroid eye disease pipeline. While the debt repayment tidies the balance sheet, the company still faces heavy cash burn, minimal revenue, and significant clinical, regulatory, and launch execution risks.
Viridian Therapeutics (VRDN) Jefferies Global Healthcare Conference 2026 Summary
Viridian Therapeutics presented at the Jefferies Global Healthcare Conference 2026, highlighting significant progress in its pipeline, particularly for thyroid eye disease (TED) treatments. The company expects immediate launch readiness for its first commercial product following a PDUFA date of June 30, 2026, and anticipates rapid revenue growth driven by its differentiated IV and subcutaneous therapies. They also provided updates on their FcRn programs and market strategy for the under-penetrated TED market.
RBC Capital raises Viridian Therapeutic stock price target to $34 on trial data
RBC Capital increased its price target for Viridian Therapeutic (NASDAQ:VRDN) to $34 from $30, maintaining an Outperform rating. This adjustment follows strong trial data for its chronic thyroid eye disease treatment, Ele', which exceeded expectations. The company also announced a $250 million capital raise to support its commercialization efforts and has a PDUFA date for Veli' set for June 30.
VRDN: Ready for TED drug launch in 2026, aiming for broad access and major market expansion
Viridian Therapeutics (VRDN) is preparing for the commercial launch of its TED drug in 2026, following a PDUFA date in June 2026. The company anticipates strong market expansion with both IV and subcutaneous options, aiming for broad access for patients. This initiative focuses on both active and chronic TED cases, supported by a robust financial strategy.
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event
Viridian Therapeutics, Inc. (VRDN) filed an 8-K report detailing the results of its 2026 Annual Meeting of Stockholders. Shareholders approved the election of two Class II directors, Tomas Kiselak and Jennifer K. Moses, the ratification of KPMG LLP as the independent registered public accounting firm, and, on an advisory basis, the compensation of named executive officers. The board also adopted an annual frequency for the advisory say-on-pay vote, aligning with stockholder preference.
How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact
Viridian Therapeutics has fully repaid its US$55.10 million Hercules term loan and secured a manufacturing agreement with WuXi Biologics for its drug veligrotug. These actions indicate a strategic shift towards reducing debt and preparing for potential product launches, aiming to improve financing flexibility and operational readiness. However, they also highlight increased focus on Viridian's cash burn and the need for future funding if commercialization is slower than anticipated.
How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact
Viridian Therapeutics has fully repaid its US$55.10 million Hercules term loan and secured a long-term manufacturing agreement with WuXi Biologics for veligrotug. These actions indicate a move towards a less leveraged balance sheet and improved operational readiness for potential product launches, reducing interest drag and cleaning up covenants. While the agreements mitigate risk and secure drug supply, they also bring a sharper focus on cash burn and potential future funding needs, especially given Viridian's ongoing losses and diverse fair value estimates in the market.
Viridian Therapeutics (NASDAQ: VRDN) retires $55.1M Hercules term loan years early
Viridian Therapeutics has fully repaid its $55.1 million term loan from Hercules Capital, significantly ahead of its scheduled October 2030 maturity. This prepayment eliminates high-cost debt with interest rates between 8.95% and 9.45% and terminates the lending arrangements, reducing future interest expense and covenant constraints. The company had borrowed $50 million under the $300 million facility.
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics announced its participation in two upcoming investor conferences in June 2026: the Leerink Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will provide live webcasts for both events, accessible on the company's website. Viridian Therapeutics is a biotechnology company specializing in therapies for autoimmune and rare diseases, with a focus on thyroid eye disease (TED) treatments.
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics, Inc. announced its participation in two upcoming investor conferences in June: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Management will provide updates on their progress in developing potential best-in-class medicines for autoimmune and rare diseases, including their advanced thyroid eye disease (TED) programs. Live webcasts and replays of the fireside chats will be available on the company's investor relations website.
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics announced its management team will attend two investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company specializes in developing medicines for autoimmune and rare diseases, including treatments for thyroid eye disease (TED) with candidates like veligrotug and elegrobart, and is also developing an anti-TSHR program and novel FcRn inhibitors. Webcasts of the presentations will be available on the company's website.
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug
Viridian Therapeutics has entered into a manufacturing agreement with WuXi Biologics for its thyroid eye disease drug. This deal signifies a step forward in the development and production of the treatment for thyroid eye disease. Financial terms of the agreement were not disclosed.
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Viridian Therapeutics, Inc. has reached an agreement with WuXi Biologics, which will manufacture and supply Viridian's investigational drug Veligrotug.
Viridian Therapeutics, Inc. has entered into an agreement with WuXi Biologics for the manufacturing and supply of its investigational drug, Veligrotug, as disclosed in SEC filings. This partnership is a critical step for Viridian, ensuring high-quality and scalable manufacturing capacity to support clinical trials and potential commercial launch. The collaboration highlights Viridian's strategic progress and execution capabilities to investors.
Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing
Viridian Therapeutics has signed a Commercial Manufacturing Services Agreement with WuXi Biologics for the long-term supply of veligrotug drug substance and drug product, contingent on regulatory approval. This non-exclusive, five-year agreement allows Viridian flexibility with other manufacturers and features volume-based pricing with fixed service fees until December 31, 2026. The deal outlines rolling monthly forecasts, with a portion becoming binding commitments, ensuring scalable manufacturing while providing termination clauses for material breach or adverse legal changes.
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)?
Viridian Therapeutics recently completed an upsized US$350 million public offering, consisting of convertible senior notes and an equity sale, to repay debt, fund thyroid eye disease market expansion, and advance research. While this financing strengthens the balance sheet and reduces near-term pressure, it also introduces further dilution and doesn't eliminate execution or commercialization risks for the company, which aims to become a commercial rare-disease player from a loss-making developer. Investors are advised to consider the implications of this capital raise alongside the company's valuation disparities and upcoming regulatory events.
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
Viridian Therapeutics (NASDAQ: VRDN) has priced upsized concurrent public offerings totaling $350 million. The financing includes $225 million in 1.75% convertible senior notes due 2032 and an equity offering of over 7.3 million shares at $17.00 per share. Net proceeds will be used to repay debt, fund market expansion studies for its thyroid eye disease franchise, advance early-stage research, and support general working capital.
Viridian Therapeutics releases topline phase 3 TED data elegrobart
Viridian Therapeutics announced positive topline results from its phase 3 REVEAL-2 clinical trial for elegrobart, an investigational treatment for chronic thyroid eye disease (TED). The study met its primary and key secondary endpoints, demonstrating high statistical significance in proptosis responder rates and diplopia responder rates for both Q4W and Q8W dosing regimens. Viridian plans to submit a Biologics License Application (BLA) for elegrobart in Q1 2027, aiming for the first autoinjector treatment for both active and chronic TED.
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results
The article discusses Viridian Therapeutics (VRDN) as it approaches a PDUFA decision, indicating a significant regulatory milestone for the company. It highlights the company's progress in advancing its Thyroid Eye Disease (TED) pipeline, suggesting ongoing development and potential for new treatments. Additionally, Viridian Therapeutics has reported its Q1 results, providing financial and operational updates to stakeholders.
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026 - News and Statistics
HighVista Strategies sold 238,243 shares of Viridian Therapeutics, valued at approximately $7.08 million, during Q1 2026 as revealed in a recent SEC filing. This divestment occurs as Viridian Therapeutics approaches a critical FDA decision deadline for its lead therapy, veligrotug, and has seen its stock rise by 35% over the past year. The company is a clinical-stage biotechnology firm focused on treatments for thyroid eye disease, with potential for a differentiated commercial approach with its subcutaneous candidate, elegrobart.
